Latest News

11 September 2025

HaemaLogiX wins “Most Promising CAR-T Pipeline in APAC” at the Asia Pacific CGT Excellence Awards 2025

HaemaLogiX was honoured to be awarded the “Most Promising CAR-T Pipeline in APAC” at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night.

Read article +
20 August 2025

HaemalogiX CEO Damian Clarke-Bruce presents at 19th Bioshares Biotech Summit in Hobart

HaemalogiX CEO Damian Clarke-Bruce presented at the 19th Bioshares Biotech Summit in Hobart, showcasing the company’s pioneering immunotherapies for multiple myeloma and B-cell disorders.

Read article +
14 June 2024

HaemaLogiX presents important new pre-clinical data at EHA2024 in Madrid

HaemaLogiX is delighted to be sharing the results of new pre-clinical data at the European Association of Hematology Congress, EHA2024, taking place this week in Madrid, Spain.

Read article +
20 May 2024

HaemaLogiX welcomes former Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director

HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Federal Minister for Health, to the HaemaLogiX Board as a Non-Executive Director.

Read article +
6 May 2024

HaemaLogiX's CMDO, Tertia Dex to speak at the Women in BIO and Health – Industry and Networking Forum

HaemaLogiX's CMDO, Tertia Dex will be speaking at the Women in BIO and Health – Industry and Networking Forum to be held on Wednesday 8 May 2024, at UniSC Moreton Bay, Petrie, Queensland.

Read article +